secwatch.observer — SEC 8-K summary
======================================

Issuer:     AGIOS PHARMACEUTICALS, INC. (AGIO)
CIK:        0001439222
Form:       8-K
Filed at:   2024-05-02T23:59:59+00:00
Accession:  0001439222-24-000067
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Agios Q1 2024 PYRUKYND revenue $8.2M; net loss $81.5M; mitapivat ENERGIZE-T readout Q2
--------------------------------------------------------------------------------

- PYRUKYND net revenue $8.2M in Q1 2024, up 15% sequentially; 120 patients on therapy.
- Net loss $81.5M in Q1 2024 vs $81.0M in Q1 2023; cash $714.3M as of March 31, 2024.
- Positive Phase 3 ENERGIZE results for mitapivat in non-transfusion-dependent thalassemia announced in January.
- ENERGIZE-T topline data expected Q2 2024; FDA filing for mitapivat in thalassemia planned year-end.
- Servier's vorasidenib NDA accepted with PDUFA Aug 20, 2024; Agios eligible for $200M milestone and 15% royalties.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1439222/000143922224000067/0001439222-24-000067-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1439222/000143922224000067/agio-20240502.htm
  HTML page:      https://secwatch.observer/filing/0001439222-24-000067

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer